Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Obesity weight loss market will remain a duopoly between Novo Nordisk and Eli Lilly: BofA'S Meacham
06:49pm, Monday, 26'th Jun 2023
Geoff Meacham, Bank of America Securities, joins 'Fast Money to discuss the state of the weight-loss drug market as Eli Lilly and Novo Nordisk compete for market share.
Trial anticipation for weight loss drugs shows they will be popular, says Dr. Kavita Patel
03:30pm, Monday, 26'th Jun 2023
Dr. Kavita Patel, NBC News medical contributor, joins 'Power Lunch' to discuss the anticipation for weight loss drugs.
Weight-loss drugs in development aim to replace injections with pills
03:21pm, Monday, 26'th Jun 2023
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills i
Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data
12:46pm, Monday, 26'th Jun 2023
Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.
Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss
09:36am, Monday, 26'th Jun 2023
Novo Nordisk's pill is an oral version of semaglutide, the active ingredient in the Danish company's blockbuster weight loss injections Ozempic and Wegovy.
Novo Nordisk to seek approval for oral version of top-selling weight loss treatment
03:03am, Monday, 26'th Jun 2023
Novo Nordisk (NYSE:NVO) said on Sunday that it plans to seek US and European regulatory approval of a high-dose oral version of its wight loss drug, semaglutide. Known as Wegovy and Ozempic, the ne
Novo Nordisk says obesity pill leads to 15% weight loss; availability "to be determined"
09:03pm, Sunday, 25'th Jun 2023
Drugmaker Novo Nordisk on Sunday said a late-stage trial found that a high-dose oral version of its drug semaglutide helped overweight or obese adults lose 15% of their body weight, which is in line w
Investing In European Dividend Stocks - Worth The Hassle?
05:57pm, Friday, 23'rd Jun 2023
Europe is a relevant place for investment due to its role as one of the world's leading economic areas. Europe is home to many well-established multinational companies. Major European stock indices ha
There's a 'strong desire' in big pharma to continue to acquire, says JPMorgan analyst
07:15am, Friday, 23'rd Jun 2023
Juha Anjala, co-head of EMEA health-care investment banking at JPMorgan, discusses government support for investment in life sciences, as well as innovation in the sector.
Novo Nordisk stock falls on Ozempic investigation into possible cancer link
03:36pm, Thursday, 22'nd Jun 2023
Yahoo Finance's Anjalee Khemlani reports on an investigation into a possible link between its Type 2 diabetes drug, Ozempic, and thyroid cancer.
Novo Nordisk shares slip on EMA drug safety signal
03:58am, Thursday, 22'nd Jun 2023
Novo Nordisk said on Thursday the European Union's drug watchdog had last month raised a thyroid cancer safety signal for several of its drugs including semaglutide, the active ingredient in its popul
More News Is Coming on Lilly, Novo Nordisk's New Weight-Loss Drugs
03:30am, Thursday, 22'nd Jun 2023
At a conference beginning Friday, Eli Lilly and Novo Nordisk will show off next-generation weight-loss drugs. Wall Street—and Hollywood—are already mad for their existing weight-loss products.
Novo Nordisk sues clinics allegedly selling knockoff versions of Ozempic and Wegovy
05:12pm, Tuesday, 20'th Jun 2023
Danish drugmaker Novo Nordisk initiated federal court lawsuits against medical spas and wellness clinics in New York, Texas, Florida and Tennessee.
Novo Nordisk cracks down on alleged Ozempic imitations
03:30pm, Tuesday, 20'th Jun 2023
Drug maker Novo Nordisk NVO, +0.28% on Tuesday sued five wellness spas and clinics in federal court, accusing them of unlawfully peddling what they said were modified copies of the popular drug Ozempi
Novo Nordisk says launch of weight loss drug Wegovy in new markets delayed due to US demand
11:38am, Tuesday, 20'th Jun 2023
Novo Nordisk (NYSE:NVO) executives announced on Tuesday that the launch of its obesity drug Wegovy in most of Europe will be slower than planned and the medication will likely not be sold in developin
